Bioluminescent deep-sea creatures illuminate the effectiveness of new cancer therapies

Pinterest LinkedIn Tumblr +

Researchers have developed a new laboratory tool, which is poised to improve the development and effectiveness of a burgeoning group of therapies that use patients’ immune systems to fight cancer with genetically engineered CAR-T cells.

Called the Topanga assay, the tool was inspired by the beauty of Topanga Beach in Malibu and uses the luciferase genes originally isolated from bioluminescent marine organisms, specifically certain crustaceans and deep sea shrimp, which produce extremely bright light-producing enzymes.

Scientists can use the enzymes to measure the expression of chimeric antigen receptors (CARs) on the surface of patients’ disease-fighting white blood cells or T cells.

This study was published in Scientific Reports.

“A number of academic labs and biotech companies are developing CAR-T cells directed against different cancers, but a major challenge is the lack of a fast, economical, sensitive and robust assay for the detection of the cancer-fighting CARs on the surface of immune T cells,” said Preet M. Chaudhary, MD, PhD, professor of medicine at the Keck School, chief of the Jane Anne Nohl Division of Hematology and Center for the Study of Blood Diseases, and director for blood and marrow transplant at USC Norris Comprehensive Cancer Center.

“The Topanga assay is a highly sensitive, specific, fast and economical assay that can be completed in as little as 30 minutes without the need of any expensive equipment,” explained Chaudhary, who is the corresponding author of the Topanga assay study. It is a novel luciferase-based assay for the detection of chimeric antigen receptors. We believe that the assay would have major use not only in research and development of next-generation CAR-T cell therapies, but also in the manufacturing of CAR-T cells that are in current clinical use.”

Future studies are planned to see if the Topanga assay can be used to monitor the expansion and persistence of CAR-T cells after they have been administered to patients.

This will allow physicians not only to identify patients who are at risk for a toxic reaction to these cells if they expand too quickly, but also to identify patients who are at high risk of experiencing cancer relapse if the CAR-T cells die out and do not persist long term.

Scientific Reports have also published a related study, led by Chaudhary of the Matador assay – which was also named after a Southern California Malibu beach.

The Matador assay used the luciferase genes of marine organisms to measure tumour cells destroyed by CAR-T cells.

Like the Topanga assay study, the findings included that the assay is fast, inexpensive and has many possible applications in biomedical research and cellular therapy manufacturing.

Source: University of Southern California – Health Sciences


About Author

ONA Editor

The ONA Editor curates oncology news, views and reviews from Australia and around the world for our readers. In aggregated content, original sources will be acknowledged in the article footer.

Leave A Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.